TIMOTHY D. MOORE, B. PHARM.; SHIV K. SETH, PH. D.
To the editor: "Guidelines for Drug Therapy in Renal Failure" by Bennett and colleagues (1) provides valuable information to the practitioner. Individualization of drug therapy by monitoring serum levels is preferred because of the great variation among patients in pharmacokinetics. The following case illustrates potential problems in using average patient data when adjusting cefazolin doses in decreased renal function.
A 26-year-old white man was admitted to The Ohio State University Hospitals on 18 July 1977. He gave a history of renal disease for 3 years and had been on chronic hemodialysis since April 1974. In June 1977 he underwent cadaveric
MOORE TD, SETH SK. Long Half-Life for Cefazolin in Anuria. Ann Intern Med. ;88:269–270. doi: 10.7326/0003-4819-88-2-269_3
Download citation file:
Published: Ann Intern Med. 1978;88(2):269-270.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use